BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agersø H, Brophy DF, Pelzer H, Martin EJ, Carr M, Hedner U, Ezban M. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011;9:333-8. [PMID: 21114621 DOI: 10.1111/j.1538-7836.2010.04152.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Simioni P, Spiezia L. Reprint of: Factor VIIa-AT complex plasma levels and arterial thrombosis. Thrombosis Research 2012;130:141. [DOI: 10.1016/j.thromres.2012.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Simioni P, Spiezia L. Factor VIIa-AT complex plasma levels and arterial thrombosis. Thromb Res 2011;128:507. [PMID: 21995975 DOI: 10.1016/j.thromres.2011.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Hedner U, Ezban M. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul Fibrinolysis 2011;22:541-6. [PMID: 21681082 DOI: 10.1097/MBC.0b013e328348d9e5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012;120:891-9. [PMID: 22563088 DOI: 10.1182/blood-2011-11-393371] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
5 Grandoni J, Duretz V, Bonzo D, Evans S, Plantier JL. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma. Haemophilia 2021;27:321-8. [PMID: 33550714 DOI: 10.1111/hae.14253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Linari S, Castaman G. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence. Ther Clin Risk Manag 2020;16:461-9. [PMID: 32547043 DOI: 10.2147/TCRM.S205310] [Reference Citation Analysis]
7 Spiezia L, Campello E, Valle FD, Woodhams B, Simioni P. Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. Clinical Chemistry and Laboratory Medicine (CCLM) 2017;55. [DOI: 10.1515/cclm-2016-0399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
8 de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012;10:81-9. [PMID: 22470921 DOI: 10.1111/j.1538-7836.2011.04549.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
9 Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014;12:220-8. [PMID: 24641308 DOI: 10.1111/jth.12477] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
10 Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost 2021;19:1687-96. [PMID: 33819375 DOI: 10.1111/jth.15323] [Reference Citation Analysis]
11 Gopalakrishnan R, Pendurthi UR, Hedner U, Agersø H, Esmon CT, Rao LV. Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa. J Thromb Haemost 2012;10:971-3. [PMID: 22372829 DOI: 10.1111/j.1538-7836.2012.04670.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Agersø H, Kristensen NR, Østergaard H, Karpf DM, Hermit MB, Pelzer H, Petersen LC, Ezban M. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs. European Journal of Pharmaceutical Sciences 2011;42:578-83. [DOI: 10.1016/j.ejps.2011.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
13 Sim DS, Mallari CR, Teare JM, Feldman RI, Bauzon M, Hermiston TW. In vitro characterization of CT-001-a short-acting factor VIIa with enhanced prohemostatic activity. Res Pract Thromb Haemost 2021;5:e12530. [PMID: 34263099 DOI: 10.1002/rth2.12530] [Reference Citation Analysis]
14 Bauer KA, Nguyen-cao TM, Spears JB. Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency. Ann Pharmacother 2016;50:758-67. [DOI: 10.1177/1060028016651276] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
15 Lee D, Nayak S, Martin SW, Heatherington AC, Vicini P, Hua F. A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects. J Thromb Haemost 2016;14:2430-45. [PMID: 27666750 DOI: 10.1111/jth.13515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Larsen MS, Juul RV, Groth AV, Simonsson US, Kristensen AT, Knudsen T, Agersø H, Kreilgaard M. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia. European Journal of Pharmaceutical Sciences 2018;115:196-203. [DOI: 10.1016/j.ejps.2018.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; the Marzeptacog alfa (activated) Study Group Investigators. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. J Thromb Haemost 2018;16:1984-93. [DOI: 10.1111/jth.14247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
18 Böhm E, Seyfried BK, Dockal M, Graninger M, Hasslacher M, Neurath M, Konetschny C, Matthiessen P, Mitterer A, Scheiflinger F. Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells. BMC Biotechnol 2015;15:87. [PMID: 26382581 DOI: 10.1186/s12896-015-0205-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
19 Grandoni J, Perret G, Forier C. Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia. Haemophilia 2017;23:300-8. [PMID: 27995727 DOI: 10.1111/hae.13110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Larsen MS, Vestergaard Juul R, Zintner SM, T Kristensen A, Margaritis P, Kjelgaard-Hansen M, Wiinberg B, Simonsson USH, Kreilgaard M. Rotational thromboelastometry can predict the probability of bleeding events in a translational rat model of haemophilia A following gene-based FVIIa prophylaxis. Haemophilia 2020;26:164-72. [PMID: 31797491 DOI: 10.1111/hae.13899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Fernández-bello I, Stenmo C, Butta N, Lind V, Ezban M, Jiménez-yuste V. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. Haemophilia 2017;23:868-76. [DOI: 10.1111/hae.13312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov 2018;17:493-508. [PMID: 29880919 DOI: 10.1038/nrd.2018.70] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
23 Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018;16:2362-74. [DOI: 10.1111/jth.14296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
24 Yeom RS, Wang XA, Elia E, Yoon U. Severe Congenital Factor VII Deficiency with Normal Perioperative Coagulation Profile Based on ROTEM Analysis in a Hepatectomy. Am J Case Rep 2021;22:e930245. [PMID: 34375324 DOI: 10.12659/AJCR.930245] [Reference Citation Analysis]
25 Słomka A, Świtońska M, Sinkiewicz W, Żekanowska E. Assessing Circulating Factor VIIa-Antithrombin Complexes in Acute Ischemic Stroke: A Pilot Study. Clin Appl Thromb Hemost 2017;23:351-9. [PMID: 26873107 DOI: 10.1177/1076029616631424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
26 Fazavana JG, Muczynski V, Proulle V, Wohner N, Christophe OD, Lenting PJ, Denis CV. LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex. J Thromb Haemost 2016;14:2458-70. [PMID: 27614059 DOI: 10.1111/jth.13502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Bernardi F, Mariani G. Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis. Haematologica 2021;106:351-62. [PMID: 33406812 DOI: 10.3324/haematol.2020.248542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Nielsen AL, Sorensen AB, Holmberg HL, Gandhi PS, Karlsson J, Buchardt J, Lamberth K, Kjelgaard-Hansen M, Ley CD, Sørensen BB, Ruf W, Olsen OH, Østergaard H. Engineering of a membrane-triggered activity switch in coagulation factor VIIa. Proc Natl Acad Sci U S A 2017;114:12454-9. [PMID: 29109275 DOI: 10.1073/pnas.1618713114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Vatsyayan R, Kothari H, Mackman N, Pendurthi UR, Rao LV. Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor. PLoS One 2014;9:e103505. [PMID: 25102166 DOI: 10.1371/journal.pone.0103505] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
30 Körber MK, Langer E, Kaufner L, Sander M, Von Heymann C. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates. Blood Transfus 2016;14:481-6. [PMID: 27177413 DOI: 10.2450/2016.0205-15] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
31 Vestergaard B, Appa RS, Lykkesfeldt J, Agersø H. The kidneys play an important role in the clearance of rFVIIa in rats. Thromb Res 2014;133:1124-9. [PMID: 24731563 DOI: 10.1016/j.thromres.2014.03.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Körber MK, Langer E, Ziemer S, Perzborn E, Gericke C, Heymann CV. Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban: An In Vitro Study. Clin Appl Thromb Hemost 2014;20:735-40. [DOI: 10.1177/1076029613494468] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
33 Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev 2016;30:92-9. [PMID: 26968829 DOI: 10.1016/j.tmrv.2016.01.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
34 Agersø H, Tranholm M. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. Haemophilia 2012;18 Suppl 5:6-10. [PMID: 22757678 DOI: 10.1111/j.1365-2516.2012.02886.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]